SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood


Por: Ng D.L., Goldgof G.M., Shy B.R., Levine A.G., Balcerek J., Bapat S.P., Prostko J., Rodgers M., Coller K., Pearce S., Franz S., Du L., Stone M., Pillai S.K., Sotomayor-Gonzalez A., Servellita V., Martin C.S.S., Granados A., Glasner D.R., Han L.M., Truong K., Akagi N., Nguyen D.N., Neumann N.M., Qazi D., Hsu E., Gu W., Santos Y.A., Custer B., Green V., Williamson P., Hills N.K., Lu C.M., Whitman J.D., Stramer S.L., Wang C., Reyes K., Hakim J.M.C., Sujishi K., Alazzeh F., Pham L., Thornborrow E., Oon C.-Y., Miller S., Kurtz T., Simmons G., Hackett J., Jr., Busch M.P., Chiu C.Y.

Publicada: 1 ene 2020
Resumen:
Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3–11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity. © 2020, The Author(s).

Filiaciones:
Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States
Department of Pathology, University of California, San Francisco, San Francisco, CA, United States
Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, United States
Vitalant Research Institute, San Francisco, CA, United States
UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, United States
Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA, United States
Creative Testing Solutions, Tempe, AZ, United States
Department of Neurology, University of California, San Francisco, San Francisco, CA, United States
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States
Laboratory Medicine Service, San Francisco VA Health Care System, San Francisco, CA, United States
American Red Cross, Gaithersburg, MD, United States
Department of Medicine at ZSFG, The Division of HIV, ID & Global Medicine, San Francisco, CA, United States
ISSN: 20411723
Editorial
NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 11 Número: 1
Páginas:
WOS Id: 000607167400002
ID de PubMed: 32943630
imagen All Open Access, Gold

MÉTRICAS